Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage

Area of Science:

• Gastroenterology
• Oncology
• Regenerative Medicine

Background:

• Glucagon-like peptide-2 (GLP-2) and its analogue teduglutide exhibit intestinotrophic properties.
• These peptides increase villus height, crypt size, and intestinal weight, potentially by stimulating stem cells.
• This suggests a role in intestinal healing and as anti-mucositis agents during cancer chemotherapy.

Purpose of the Study:

• To investigate the protective effects of teduglutide on the murine small intestinal epithelium after gamma-irradiation.
• To assess teduglutide's impact on crypt stem cell survival and functional competence using the crypt microcolony assay.

Main Methods:

• Teduglutide was administered to CD1 and BDF1 mice to assess intestinotrophic effects.
• BDF1 mice received subcutaneous injections of GLP-2 or teduglutide (0.2 mg/kg/day, b.i.d.) for 14 days.
• Teduglutide was administered daily for 6 or 14 days before whole-body gamma-irradiation in BDF1 mice.

Main Results:

• Teduglutide demonstrated intestinotrophic effects in both mouse strains.
• In BDF1 mice, teduglutide increased intestinal weight by 28%, with comparable increases in crypt size, villus height, and area.
• Pre-irradiation administration of teduglutide significantly increased crypt stem cell survival, with protection factors ranging from 1.3 to 1.5.

Conclusions:

• Teduglutide effectively modulates clonogenic stem cell survival in the small intestine.
• The protective effect is observed when teduglutide is administered prior to irradiation.
• Teduglutide shows potential clinical utility in preventing cancer therapy-induced mucositis.